DPP4 and gout: After considering potential risk factors, dapagliflozin users had an HR of 0.86 (95% CI, 0.78-0.95, P = .002), and empagliflozin users had an HR of 0.93 (95% CI, 0.84-1.03, P = .16) for incidence of gout compared with DPP4 inhibitor users.